The Life Sciences team advised Corbus Pharmaceuticals on its strategic collaboration with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the clinical development and commercialization in Japan of Corbus’ investigational drug Lenabasum for the treatment of systemic sclerosis and dermatomyositis, two rare and serious autoimmune diseases.
Under the terms of the agreement, Kaken received an exclusive license to commercialize and market Lenabasum in Japan for systemic sclerosis and dermatomyositis. Kaken will make an upfront payment to Corbus of $27 million. Corbus is eligible to receive in addition up to $173 million upon achievement of certain regulatory, development and sales milestones, as well as double-digit royalties on sales of Lenabasum in Japan.
Corbus Pharmaceuticals is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates.
For additional details on the collaboration, please read the press release.